Quick Takeaways
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX).
- Disclosed ownership: 8.2%.
- Date of event: 30 Sep 2025.
PERCEPTIVE ADVISORS LLC - 30 Sep 2025 SCHEDULE 13G/A Report for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Perceptive Advisors LLC
- Symbol
- AMLX
- Shares outstanding
- 109,175,183 shares
- Disclosed Ownership
- 8,952,365 shares
- Ownership
- 8.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Nov 2025, 16:00:03 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PERCEPTIVE ADVISORS LLC disclosed 8.2% ownership in Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Nov 2025, 16:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 8.2% | 8,952,365 | 0 | 8,952,365 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | |
| Joseph Edelman | 8.2% | 8,952,365 | 0 | 8,952,365 | /s/ Joseph Edelman | Joseph Edelman | |
| Perceptive Life Sciences Master Fund, Ltd. | 8.2% | 8,952,365 | 0 | 8,952,365 | /s/ Joseph Edelman | Joseph Edelman, Managing Member |